Sharemaestro Newsreel

KMDA|Kamada Ltd|Price:7.070|Chg%:+0.080

This article provides a detailed stock analysis for Kamada Ltd (KMDA), highlighting its current market trends, financial performance, and analyst ratings. Based on three analysts, the stock has a "Buy" rating with a target price of $13.00, representing an 84.14% upside. While Kamada Ltd …

OGI|OrganiGram Holdings Inc|Price:0.929|Chg%:-0.019

This article provides a comprehensive stock analysis of OrganiGram Holdings Inc (OGI) by TradingKey, assigning it a score of 4.59 out of 10. The analysis highlights the company's significant growth potential, stable fundamentals, and fair valuation, despite recent weak market performance. It also details …

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS)

Generic Pharmaceuticals Stocks Q1 Highlights: Viatris (NASDAQ:VTRS) The end of the earnings season is always a good time to take a step back and see who shined (and who didn't). Let's take a look at how generic pharmaceuticals stocks fared in Q1, starting with …

Biofrontera Inc. Revenue Breakdown – NASDAQ:BFRI

Biofrontera Inc. (NASDAQ: BFRI) generated $41.70 million in revenue last year, primarily from its Pharmaceutical Products segment. This revenue marks an increase from $37.32 million in the previous year. The United States was the company's sole significant regional contributor, accounting for all reported revenue.

Cumberland Pharmaceuticals Q2 Results: Company update and earnings call set for Aug 4

Cumberland Pharmaceuticals Inc. will release its Q2 2026 financial results and provide a company update on August 4, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results, with a replay available for one year. The company …

Tilray rises despite missing FQ4 bottom line on strong FY27 EBITDA growth guidance

[Fourth Quarter Q4 Profits Stock Trading Chart 3D Background] * Tilray Brands (TLRY [https://seekingalpha.com/symbol/TLRY]) is up ~3% in after-hours trading Tuesday after its FQ4 EPS results missed [https://seekingalpha.com/news/4619781-tilray-non-gaap-eps-of-0_11-misses-by-0_10-revenue-of-281_71m-beats-by-35_41m] expectations as its full-year EBITDA guidance of $68M-$75M represents double-digit year-over-year growth. * Though a miss, …

United Therapeutics CEO Rothblatt sells $5 million in shares

Martine A. Rothblatt, CEO of United Therapeutics Corp, sold 9,500 shares for approximately $5 million on July 28, 2026, after exercising stock options. This transaction was part of a pre-arranged 10b5-1 trading plan adopted in November 2025. Despite the insider sale, the company has …

Form 4 United Therapeutics Corporation For: 28 July By Investing.com

The article reports on a Form 4 filing for United Therapeutics Corporation (UTHR) which was made on July 28. It provides minimal details about the filing itself, primarily serving as an announcement of the document's existence rather than offering insights into its content. The …

Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High - What's Next?

Eton Pharmaceuticals (NASDAQ:ETON) recently hit a new 52-week high of $45.27, trading near $44.91, following a consensus "Moderate Buy" rating and an average price target of $52.50 from analysts. Despite beating revenue expectations, the company missed EPS estimates in its latest quarter, and insiders …

EcoR1 Capital LLC Purchases 141,394 Shares of Eton Pharmaceuticals, Inc. $ETON

EcoR1 Capital LLC has increased its stake in Eton Pharmaceuticals (NASDAQ:ETON) by 7%, purchasing an additional 141,394 shares to own 7.93% of the company, valued at approximately $53.6 million. Despite a "Moderate Buy" consensus rating and a $45.75 target price from analysts, company insiders …

Form 4 Elanco Animal Health For: 28 July By Investing.com

This Investing.com article reports on a Form 4 filing for Elanco Animal Health for July 28. It includes the company's stock symbol ELAN and notes its current performance with a slight increase. The article provides a brief update on insider transaction filings for the …

Elanco Animal Health Inc (NYSE: ELAN) awards deferred stock units

Elanco Animal Health Inc (NYSE: ELAN) reported that EVP Rajeev A. Modi was granted 59.2906 deferred stock units on July 24, 2026, with a reference value of $24.91 per unit. These units, which represent the right to receive one share of common stock or …

BlackRock (ETON stakeholder) reports 6.9% ownership in Eton Pharmaceuticals common stock

BlackRock, Inc. has filed an amended Schedule 13G/A report indicating a beneficial ownership of 1,882,410 shares of Eton Pharmaceuticals, Inc. common stock, which represents 6.9% of the outstanding class as of June 30, 2026. The filing shows BlackRock holds sole voting power over 1,850,186 …

Stronger Q2 Results And Higher 2026 Outlook Might Change The Case For Investing In Kiniksa (KNSA)

Tilray Brands Releases Q4 2026 Financial Results

Tilray Brands, Inc. reported mixed financial results for Q4 2026, with adjusted earnings per share missing analyst estimates at $0.05 against an expected $0.21, representing a 76.2% miss. However, the company's revenue exceeded expectations, reaching $281.7 million, a 14.4% beat over the consensus and …

BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood

BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares. The filing specifies …

Lantheus Holdings, Inc. Stock 12‑Month Price Target Raised to $113.82, Implies 5% Upside

Lantheus Holdings, Inc. (LNTH) has seen its average 12-month price target raised to $113.82 by 11 analysts, up from $112.91. This new target suggests a potential 5% upside based on the July 27 closing price. The consensus analyst rating remains a "Buy" across 14 …

BCRX|BioCryst Pharmaceuticals Inc|Price:9.609|Chg%:-0.131

This article provides a comprehensive stock analysis of BioCryst Pharmaceuticals Inc (BCRX), highlighting its relatively healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes strong institutional ownership, a consensus "Buy" rating from analysts with a …

Cumberland's ifetroban is in Phase 2 studies for four diseases

Cumberland Pharmaceuticals (Nasdaq: CPIX) announced it will release its Q2 2026 financial results and a company update on Tuesday, August 4, 2026, after market close, followed by a conference call. The Tennessee-based biopharmaceutical company is focused on rare diseases and is progressing its late-stage …

Phibro shareholders set to receive $0.12 dividend Sept. 23

Phibro Animal Health Corporation announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on September 23, 2026, to stockholders of record as of September 2, 2026. Phibro Animal Health is a …

Phibro Animal Health declares $0.12 quarterly dividend payable Sept. 23

Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend is payable on September 23, 2026, to shareholders of record as of September 2, 2026. This announcement was filed …

Eton Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ETON

This article provides a revenue breakdown for Eton Pharmaceuticals Inc (ETON), focusing on its business segments and regional contributions. It notes that relevant data for FY2025 and its quarters, as well as FY2024, have not yet been disclosed by the company. However, it does …

Rockwell Medical, Inc. Revenue Breakdown – LSX:A42EKB

Rockwell Medical, Inc. (A42EKB on Lang & Schwarz Exchange) reported a total revenue of €58.97 million last year, down from €97.99 million in the previous year. The majority of this revenue, €58.69 million, was generated from its Concentrate Products segment. The United States was …

Alkermes PLC (ALKS) Q2 2026 Earnings Call Highlights: Strong Sales Growth Amidst Competitive ...

This article first appeared on GuruFocus. Release Date: July 28, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Alkermes PLC (NASDAQ:ALKS) reported a 34% year-over-year increase in net sales from its proprietary product …

How Investors Are Reacting To Supernus Pharmaceuticals (SUPN) Positive Earnings ESP And Renewed Beat Expectations

Supernus Pharmaceuticals (SUPN) is attracting investor attention due to a positive Earnings ESP and a history of beating earnings expectations ahead of its early August 2026 release. While this fuels optimism for another beat, the core investment narrative relies on the company's ability to …

TEVA Looks 55.9% Overvalued on GF Value™ as Earnings Outlook Dims

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is projected to report a significant 83% drop in Q2 2026 earnings per share and a 4% revenue decline. Despite beating expectations in the previous quarter, the company lowered full-year guidance due to an acquisition and faces ongoing …

Teva Pharmaceutical Inds Number of Employees 2026 | Employee Count & Headcount Data

Teva Pharmaceutical Industries Ltd. (TEVA) had approximately 33,327 employees worldwide as of March 2026, marking a 2.8% decline from 2023. The company is actively hiring with 968 job postings in 2026, a 3.7% increase from the previous year, and its workforce is concentrated in …

Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness

Tilray Brands, Inc. reported record fiscal year 2026 net revenue of $915 million and record adjusted EBITDA of $61.1 million, showcasing the strength of its diversified global platform across cannabis, beverage, hospitality, and wellness. The company achieved significant growth in international medical cannabis revenue …

Viatris Inc. stock rises Tuesday, outperforms market

Viatris Inc. (VTRS) stock rose 1.28% on Tuesday, closing at $17.86. This performance outpaced the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw gains. The increase marks the second consecutive day of gains for Viatris stock.

ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock?

Shares of Eton Pharmaceuticals Inc (ETON) jumped 10% after Craig-Hallum raised its price target to $62 from $40, maintaining a 'Buy' rating. The firm's optimism stems from new products like Amglidia and an acquired generic drug application, alongside more positive sales projections for existing …

KNSA Stock Jumps As Wall Street Boosts Price Targets

Kiniksa Pharmaceuticals International plc (KNSA) stock surged by 22.7% after Wedbush, Wells Fargo, and Goldman Sachs raised their price targets, citing strong momentum for its drug Arcalyst and a large market opportunity. The increased targets range from $72 to $75, though analysts also warned …

Neurocrine Biosciences stock hits all-time high at 181.3 USD

Neurocrine Biosciences Inc. (NBIX) reached an all-time stock high of $181.30, reflecting a 34.56% increase over the past year. Analysts have revised earnings estimates upward, and the stock trades at a PEG ratio of 0.22, suggesting it remains undervalued according to InvestingPro analysis despite …

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

Alkermes plc reported break-even earnings for Q2 2026, surpassing the Zacks Consensus Estimate of a loss, while revenues of $496 million beat estimates. The company saw a 27% increase in total revenues year-over-year, driven by strong proprietary product sales, yet its stock declined in …

Piper Sandler Raises Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $44.00

Piper Sandler has increased its price target for Teva Pharmaceutical Industries (NYSE:TEVA) to $44.00 from $42.00, maintaining an "overweight" rating and suggesting a potential upside of over 40% from its current price. This follows a trend of positive analyst sentiment, with a consensus "Moderate …

Regencell Bioscience Holdings Ltd (RGC) Cash Flow

This article provides an overview of Regencell Bioscience Holdings Ltd's (RGC) cash flow, including operating, investing, and financing cash flow, along with free cash flow. It details the company's operating cash flow for fiscal 2025, its year-over-year change, and capital expenditures for the most …

Cumberland Pharmaceuticals (CPIX) Projected to Announce Earnings on Tuesday

Cumberland Pharmaceuticals (CPIX) is expected to release its Q2 2026 earnings before the market opens on Tuesday, August 4th, with analysts forecasting a loss of $0.13 per share and revenue of $8.50 million. The company's previous quarter saw it meet loss estimates while exceeding …